Zsírmáj (MASLD/MASH): vizsgálatok itt: Kína
40 of 73 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Jiaxing, Kunming, Liaocheng, Luoyang, Nanchang, Nanjing, Ningbo, Ningxia, Pingxiang, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Xi'an, Zhengzhou, Zhenjiang
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - 2. fázisTaking peopleTesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 120
- Run by
- Hudson Biotech
See details and how to joinNCT07481734 - 3. fázisNot yet taking people in KínaELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
- Where
- Chengdu, Luoyang, Nanjing, Shanghai
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07850063 · EU 2026-527091-88-00 - 2. fázisTaking peopleA Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 156
- Run by
- The United Bio-Technology (Hengqin) Co., Ltd.
See details and how to joinNCT07145151 - 3. fázisTaking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang, Hangzhou, Jiaxing, Liaocheng, Luoyang, Nanchang, Nanjing, Ningbo, Ningxia, Pingxiang, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xuzhou, Yanji, Yueyang, Yuncheng, Zhengzhou, Zhenjiang
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - 1/2. fázisTaking peopleHigh-Plant-Protein-Diet or High-Animal-Protein-Diet for Improving Alcoholic Fatty Liver Disease
- Where
- Hangzhou
- Életkor
- 18 év to 74 év
- People
- 74
- Run by
- Li Lab,MD
See details and how to joinNCT07897981 - No phaseNot yet taking people in KínaiWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 216
- Run by
- Liu Yan
See details and how to joinNCT07237750 - 2. fázisNot yet taking people in KínaA Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 120
- Run by
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
See details and how to joinNCT07878091 - 3. fázisTaking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang, Hangzhou, Jinhua, Liaocheng, Luoyang, Luzhou, Nanchang, Nanjing, Nanyang, Ningbo, Pingxiang, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Xi’an, Yinchuan, Zhoukou
- Életkor
- 18 év and over
- People
- 4500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - 3. fázisTaking peopleA Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 886
- Run by
- Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07581951 - 4. fázisTaking peoplePre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
- Where
- Beijing, Chengdu, Chongqing, Hefei
- Életkor
- 18 év to 60 év
- People
- 60
- Run by
- West China Hospital
See details and how to joinNCT07718126 - 1. fázisTaking peopleA Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
- Where
- Chengdu
- Életkor
- 18 év to 65 év
- People
- 32
- Run by
- Fujian Shengdi Pharmaceutical Co., Ltd.
See details and how to joinNCT07807059 - 1. fázisNot yet taking people in KínaSafety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)
- Where
- Beijing, Shanghai, Xiamen, Xi’an
- Életkor
- 18 év to 69 év
- People
- 24
- Run by
- Xiamen Amoytop Biotech Co., Ltd.
See details and how to joinNCT07462455 - 1. fázisTaking peoplePhase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
- Where
- Kunming
- Életkor
- 18 év to 50 év
- People
- 36
- Run by
- Shanghai Minwei Biotechnology Co., Ltd
See details and how to joinNCT07803809 - 2. fázisTaking peopleA Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis
- Where
- Beijing, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 160
- Run by
- Fujian Shengdi Pharmaceutical Co., Ltd.
See details and how to joinNCT07660848 - No phaseNot yet taking people in KínaMetformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD
- Where
- Putian
- Életkor
- 30 év to 60 év
- People
- 84
- Run by
- The 95th Hospital of Putian,Putian, Fujian, China
See details and how to joinNCT07778719 - 3. fázisNot yet taking people in KínaA Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 480
- Run by
- Zhejiang Doer Biologics Co., Ltd.
See details and how to joinNCT07693777 - 1/2. fázisTaking peopleDihydroartemisinin for MAFLD
- Where
- Nanjing
- Életkor
- 18 év to 45 év
- People
- 30
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07679542 - 2. fázisTaking peopleA Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
- Where
- Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shiyan, Tianjin, Ürümqi, Wuhan, Xi’an
- Életkor
- 18 év to 75 év
- People
- 300
- Run by
- Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07303803 - 4. fázisTaking peopleThe Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
- Where
- Jiangxi
- Életkor
- 18 év to 75 év
- People
- 100
- Run by
- Second Affiliated Hospital of Nanchang University
See details and how to joinNCT07272343 - Korai 1. fázisNot yet taking people in KínaA Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
- Where
- Jilin City
- Életkor
- 18 év to 65 év
- People
- 94
- Run by
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
See details and how to joinNCT07407634 - Korai 1. fázisTaking peopleEfficacy and Safety of Rifaximin-α in Treating MASLD
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07381257 - 2. fázisTaking peopleA Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
- Where
- Beijing, Chengdu
- Életkor
- 18 év to 65 év
- People
- 80
- Run by
- Hinova Pharmaceuticals Inc.
See details and how to joinNCT07308548 - 2/3. fázisTaking peopleThe Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 20
- Run by
- Eastern Hepatobiliary Surgery Hospital
See details and how to joinNCT07285850 - Korai 1. fázisTaking peopleEfficacy and Safety of Rifaximin in Treating MAFLD
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07185932